Trial Profile
A study of APR-246 for the reatment of myelodysplastic syndrome (MDS)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 30 May 2017
Price :
$35
*
At a glance
- Drugs Eprenetapopt (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 30 May 2017 New trial record
- 23 May 2017 According to an Aprea Therapeutics media release, first patient was enrolled in this study.